Research and Development

Peter Culpepper, chief operating officer at Provectus Biopharmaceuticals, explains the secrets of Rose Bengal, which has impressed in clinical trials …

GSK is charging up to four times more for its recently approved asthma drug Nucala than is justified by cost-effectiveness …

Janssen has announced a new collaboration and license agreement with Bavarian Nordic to develop a vaccine for chronic Human Papillomavirus …

Merck and Pfizer have announced the opening of trial sites for an international Phase III study of avelumab in patients …

Actelion says it is ready to launch Uptravi, its drug for pulmonary arterial hypertension in the US in January, after …

Shire is set to sweeten its $30 billion bid for Baxalta by offering 40% of the total, or $12 billion, …

Michael Bonney, current board member and former chief executive of Cubist Pharmaceuticals, has been appointed as chairman of Alnylam Pharmaceuticals …

MSD’s Keytruda significantly improved overall survival (OS) compared to chemotherapy in people with lung cancer and PD-L1 expression, a trial …

Novartis has completed the acquisition of all outstanding rights to Arzerra from GSK for up to $1.034 billion. The deal, …

Dr Arnaud Lallouette has been appointed chief executive of Servier Laboratories, the UK subsidiary of the French-based pharma firm, after …

Timothy Walbert, the chairman, president and chief executive of Horizon Pharma, has been elected as chairman of the board of …

Specialist HIV company ViiV Healthcare has agreed deals worth up to $1.46 billion to purchase Bristol-Myers Squibb’s late stage HIV …

The number of clinical trials funded by pharma has risen significantly since 2006, while the number funded by the US …

Novartis has hired James ‘Jay’ Bradner, from Harvard’s Dana-Farber Cancer Institute, to head its Institutes for Biomedical Research from 1 …

Gilead Science’s hepatitis C treatment Sovaldi has been awarded the British Pharmacological Society’s prestigious Drug Discovery of the Year 2016. …